Basit öğe kaydını göster

ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.

dc.contributor.authorLiu, Qi
dc.contributor.authorTOPUZ, Samet
dc.contributor.authorPautier, Patricia
dc.contributor.authorCibula, David
dc.contributor.authorLheureux, Stephanie
dc.contributor.authorHasegawa, Kosei
dc.contributor.authorKim, Byoung-Gie
dc.contributor.authorLai, Chyong-Huey
dc.contributor.authorGonzalez-Martin, Antonio
dc.contributor.authorKeefe, Stephen Michael
dc.contributor.authorPuglisi, Martina
dc.contributor.authorVergote, Ignace
dc.contributor.authorSehouli, Jalid
dc.contributor.authorSalutari, Vanda
dc.contributor.authorZola, Paolo
dc.contributor.authorMadry, Radoslaw
dc.contributor.authorWenham, Robert Michael
dc.contributor.authorKorach, Jacob
dc.date.accessioned2022-02-18T10:15:44Z
dc.date.available2022-02-18T10:15:44Z
dc.identifier.citationVergote I., Sehouli J., Salutari V., Zola P., Madry R., Wenham R. M. , Korach J., Pautier P., Cibula D., Lheureux S., et al., "ENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.", Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37
dc.identifier.othervv_1032021
dc.identifier.otherav_8a402250-ca50-4a50-a59f-fd61502d46d6
dc.identifier.urihttp://hdl.handle.net/20.500.12627/178890
dc.identifier.urihttps://doi.org/10.1200/jco.2019.37.15_suppl.tps5603
dc.language.isoeng
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectHealth Sciences
dc.subjectOncology
dc.titleENGOT-OV43/KEYLYNK-001: A phase Ill, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume37
dc.contributor.firstauthorID3387283


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster